Quarterly report pursuant to Section 13 or 15(d)

Royalty Purchase Agreements - Bioasis (Details)

v3.21.1
Royalty Purchase Agreements - Bioasis (Details)
$ in Thousands
 3 Months Ended 12 Months Ended
Nov. 02, 2020
USD ($)
Feb. 25, 2019
USD ($)
agreement
Mar. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Agreements        
Payments to acquire milestones and royalties     $ 13,500  
Contingent consideration under royalty purchase agreements     75 $ 75
Long-term royalty receivables     48,075 34,575
Impairment of long-term royalty receivable     0 $ 0
Bioasis Technologies Inc | Royalty Purchase Agreement        
Agreements        
Percentage of option to purchase royalty right on future license agreements   1.00%    
Number of future license agreements under optional purchase right | agreement   2    
Obligation upon exercise of options per licensed product, second agreement   $ 300    
Obligation upon exercise of options per licensed product, third agreement   400    
Payments to acquire milestones and royalties   300    
Contingent consideration under royalty purchase agreements   100    
Long-term royalty receivables   400    
Changes in estimated fair value of contingent consideration     0  
Payments of contingent consideration     0  
Impairment of long-term royalty receivable     0  
Bioasis Technologies Inc | Royalty Purchase Agreement | Maximum        
Agreements        
Potential future cash payments   $ 200    
Bioasis Technologies Inc | Second Royalty Purchase Agreement        
Agreements        
Payments to acquire milestones and royalties $ 1,200      
Long-term royalty receivables $ 1,200      
Impairment of long-term royalty receivable     $ 0